Paradoxical effects of very low dose MK-801

European Journal of Pharmacology

Volumn 537, Issue 1-3, 2006, Pages 77-84

  Tang, Yuanjia ^a   Zou, Hong ^a   Strong, Judith A ^b   Cui, Yiwen ^a   Xie, Qinglian ^a   Zhao, Guoping ^a   Jin, Meilei ^a   Yu, Lei ^b,c  

^a Chinese Academy of Sciences   (China)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

Catalepsy; Dizocilpine maleate; Haloperidol; Immobility; Locomotion; NMDA receptor antagonist

Indexed keywords

DIZOCILPINE; HALOPERIDOL;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; GROOMING; IMMOBILIZATION; LOCOMOTION; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; REARING; RODENT;

ANIMALS; BEHAVIOR, ANIMAL; CATALEPSY; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 33646467063     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.03.016     Document Type: Article

References (20)

1. Abel K.M., Allin M.P., Hemsley D.R., and Geyer M.A. Low dose ketamine increases prepulse inhibition in healthy men. Neuropharmacology 44 (2003) 729-737
2. Adriani W., Felici A., Sargolini F., Roullet P., Usiello A., Oliverio A., and Mele A. N-methyl-d-aspartate and dopamine receptor involvement in the modulation of locomotor activity and memory processes. Exp. Brain Res. 123 (1998) 52-59
3. Carlsson M., and Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13 (1990) 272-276
4. Clineschmidt B.V., Martin G.E., Bunting P.R., and Papp N.L. Central sympathomimetic activity of (+)-5-methyl-10,11-dihydro-5H-dibenzo [d]cyclohepten-5,10-immine(MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev. Res. 2 (1982) 135-145
5. Deutsch S.I., Rosse R.B., and Mastropaolo J. Behavioral approaches to the functional assessment of NMDA-mediated neural transmission in intact mice. Clin. Neuropharmacol. 20 (1997) 375-384
6. Institute of Laboratory Animal Resources. Guide for the Care and Use of Laboratory Animals (1996), National Academy Press, Washington, D.C.
7. Irifune M., Shimizu T., Nomoto M., and Fukuda T. Involvement of N-methyl-d-aspartate (NMDA) receptors in noncompetitive NMDA receptor antagonist-induced hyperlocomotion in mice. Pharmacol. Biochem. Behav. 51 (1995) 291-296
8. Jackson M.E., Homayoun H., and Moghaddam B. NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 8467-8472
9. Javitt D.C. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside. J. Clin. Psychiatry 9 (1987) 12-35
10. Kim J.S., Kornhuber H.H., Schmid-Burgk W., and Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 20 (1980) 379-382
11. Leriche L., Schwartz J.C., and Sokoloff P. The dopamine D3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade. Neuropharmacology 45 (2003) 174-181
12. Masuo Y., Noguchi J., Morita S., and Matsumoto Y. Effects of intracerebroventricular administration of pituitary adenylate cyclase-activating polypeptide (PACAP) on the motor activity and reserpine-induced hypothermia in murines. Brain Res. 700 (1995) 219-226
13. Miyamoto M., Narumi S., Nagai Y., Saji Y., and Nagawa Y. A TRH analog (DN-1417): motor stimulation with rearing related to catecholaminergic mechanisms in rats. Neuropharmacology 23 (1984) 61-72
14. Moghaddam B. Bringing order to the glutamate chaos in schizophrenia. Neuron 40 (2003) 881-884
15. Nankai M., Klarica M., Fage D., and Carter C. The pharmacology of native N-methyl-d-aspartate receptor subtypes: different receptors control the release of different striatal and spinal transmitters. Prog. Neuro-psychopharmacol. Biol. Psychiatry 22 (1998) 35-64
16. Sanberg P.R., Bunsey M.D., Giordano M., and Norman A.B. The catalepsy test: its ups and downs. Behav. Neurosci. 102 (1988) 748-759
17. Schmidt W.J., and Kretschmer B.D. Behavioural pharmacology of glutamate receptors in the basal ganglia. Neurosci. Biobehav. Rev. 21 (1997) 381-392
18. Tiedtke P.I., Bischoff C., and Schmidt W.J. MK-801-induced stereotypy and its antagonism by neuroleptic drugs. J. Neural Transm.: Gen. Sect. 81 (1990) 173-182
19. Wu J., Zou H., Strong J.A., Yu J., Zhou X., Xie Q., Zhao G., Jin M., and Yu L. Bimodal effects of MK-801 on locomotion and stereotypy in C57BL/6 mice. Psychopharmacology 177 (2005) 256-263
20. Yanahashi S., Hashimoto K., Hattori K., Yuasa S., and Iyo M. Role of NMDA receptor subtypes in the induction of catalepsy and increase in Fos protein expression after administration of haloperidol. Brain Res. 1011 (2004) 84-93